Related Experiment Video
Updated: May 12, 2026
05:12
Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy
Published on: May 12, 2023
Graves' orbitopathy: Management of difficult cases
1Department of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, Netherlands.
Indian Journal of Endocrinology and Metabolism
|April 9, 2013
Summary
Effective Graves' ophthalmopathy (GO) management requires quitting smoking, maintaining thyroid balance, and tailored eye treatment. Addressing these pillars, especially smoking cessation and varied therapeutic options for eye changes, is crucial for better patient outcomes.
Area of Science:
- Endocrinology
- Ophthalmology
Background:
- Graves' ophthalmopathy (GO) management involves addressing smoking, thyroid status, and eye manifestations.
- Challenges exist in patient smoking cessation and selecting optimal treatments for GO.
Purpose of the Study:
- To outline current strategies and challenges in managing Graves' ophthalmopathy.
- To review therapeutic options for different severities of GO and associated thyroid dysfunction.
Main Methods:
- Review of management principles for Graves' ophthalmopathy.
- Discussion of treatment modalities including smoking cessation, thyroid control, and specific therapies for eye changes.
- Consideration of treatments for mild, moderate-to-severe GO, and dysthyroid optic neuropathy.
Main Results:
- Smoking cessation is critical but difficult; patient education on risks is vital.
- Radioactive iodine (131I) therapy carries a risk of worsening GO, necessitating preventive steroids in high-risk patients.
- Intravenous methylprednisolone pulses are preferred for moderate-to-severe GO, with combination therapies and other agents for refractory cases.
Conclusions:
- Comprehensive management of Graves' ophthalmopathy requires a multi-pillar approach.
- Tailoring treatments to GO severity, patient risk factors, and response is essential.
- Emerging therapies like rituximab show potential but require further investigation.
Related Concept Videos
01:28Graves' Disease I: Introduction
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
01:24Graves Disease II: Pathophysiology
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
01:25Hyperthyroidism I: Introduction
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
01:27Hyperthyroidism II: Pathophysiology
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...